Repligen (RGEN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$167.60-1.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · RGEN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks RGEN against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Deliver organic revenue growth within the range of 10.5% to 13.5% for the full fiscal year 2026.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $182.4M in 2025-Q2 to $204.1M in 2026-Q2, a 12% reported and 13% organic increase year-over-year. Management has consistently raised and reiterated FY26 organic revenue growth guidance to 10.5%-13.5%, showing delivery and confidence in this growth trajectory.
“Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09”
“Reiterating FY26 organic revenue growth guidance of 9%-13%”
“Our initial 2026 guidance calls for 10% - 14% revenue growth”
“Increasing revenue guidance to range of $715 to $735 million, which represents 12.5% -15.5% year-over-year non-COVID organic growth”
Raise adjusted earnings per share guidance to a range of $2.03 to $2.09 for fiscal year 2026.
Stated as a priority in 4 of last 4 quarters. Adjusted EPS guidance was raised to $2.03-$2.09 for FY26. Actual diluted EPS was $0.15 in 2026-Q1 and $0.09 in 2026-Q2, reflecting some quarterly variability but management maintains the full-year EPS target, indicating ongoing delivery toward this priority.
“Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09”
Sustain an operating margin in the range of about 15.7% to 16.0% for the full year 2026.
Stated as a priority in 4 of last 4 quarters. Management targets an operating margin of approximately 15.7%-16.0% for FY26. Adjusted operating margin was 16.7% in 2026-Q2, above guidance range, indicating delivery and margin expansion consistent with stated goals.
Accelerate leadership in cell therapy by acquiring BioLife Solutions to add a consumables platform with recurring revenue and commercial-stage exposure.
Newly stated in 2026-Q2. Management announced the definitive agreement to acquire BioLife Solutions to strengthen cell therapy market presence with a differentiated consumables platform. This is a strategic growth initiative with no prior quarters stating this priority.
“Announcement of definitive agreement to acquire BioLife Solutions, fast-tracking cell therapy leadership”
Over the trailing year it converted -616.16x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Increasing adjusted EPS to $1.97-$2.05”
“Our initial 2026 guidance calls for Earnings Per Share - Diluted $1.93 - $2.01”
“Increasing adjusted EPS to $0.85 - $0.92 for 2025”
“Operating Margin 15.7% - 16.0%”
“Operating Margin 15.4% - 15.8%”
“Operating Margin 15.1% - 15.5%”
“Adjusted operating margin expansion of 150 bps at the midpoint”